Director Trades
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on ImpediMed.
RELATED STOCKHEAD STORIES
Health & Biotech
ImpediMed’s new leadership team looks to grow the company
Health & Biotech
ScoPo’s Powerplays: Health stocks fall as tight hospital budgets hurt Nanosonics
Health & Biotech
ScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after Phase III trial misses endpoint
Health & Biotech
ScoPo’s Powerplays: ASX health stocks up as Cochlear upgrades earnings guidance
ScoPo’s Powerplays: ASX health stocks up but reporting season remains a bit chilly for some
Health & Biotech
ScoPo’s Powerplays: ASX health stocks feeling the love as Avita Medical kicks off 2024 strongly
Health & Biotech
ScoPo gives his NINE picks to fill the Christmas stocking with some ASX health stocks
Health & Biotech
ScoPo’s Powerplays: ASX health stocks flat as a pancake but hopes still of Christmas rally
News
Market Highlights: Wall Street sentiment remains high, 9 most innovative firms, and 5 small caps to watch today
Health & Biotech
ScoPo’s Powerplays: Who fancies 22 minutes of exercise? And ASX health stocks are up (finally)
Health & Biotech
ASX Health Stocks: BOD says all trials are done, and it’s time to begin commercialising Aqua Phase
Health & Biotech
2023 ASX biotech darling Neuren among sector stocks with upcoming catalysts
Health & Biotech
ScoPo’s Powerplays: Mesoblast sinks Health sector, and how to live 24 years longer
News
In Case You Missed It: Gold, biotech and some gas
Health & Biotech
ASX Health Stocks: Recce Pharma and Impedimed surge 15pc after positive announcements
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech